Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Researchers at UHN have refined a detailed map of cells present in the liver by combining two advanced single-cell genetic approaches.
"Current approaches rely on the sequencing of genetic material, such as RNA, from single cells. The drawback of this approach is that the harsh detergents that are required to break up tissue can also damage fragile cells, leading to sample loss," says UHN's Ajmera Transplant Centre's Dr. Sonya MacParland, who is the co-senior author of the study, scientist at the Toronto General Hospital Research Institute (TGHRI), and Assistant Professor in the departments of Immunology and Laboratory Medicine & Pathobiology at the University of Toronto (U of T).
To improve the team's ability to detect the different types of cells found in the human liver, the team combined a single-cell RNA sequencing (RNA-seq) approach with single-nucleus RNA-seq. Single-nucleus RNA-seq does not require researchers to isolate intact cells from liver tissue. Instead, researchers isolate and analyze nuclei, the subcompartments in cells that house genetic material.
The team analyzed genetic material from 73,295 individual cells from four samples of healthy human liver tissue. By adding single-nucleus RNA-seq to their analyses, the team was able to add the following new cell types to their map of the liver:
"An added benefit of using single-nucleus RNA-seq is that we can isolate nuclei from frozen tissues. This approach opens the door for researchers to study the large collections of samples that are present in tissue biobanks," says Dr. Gary Bader, co-senior author of the study, affiliate scientist at the Princess Margaret Cancer Centre and Professor at U of T's Donnelly Centre for Cellular and Biomolecular Research.
It is important to note that single-nucleus RNA-seq cannot replace single-cell RNA-seq. Just like when researchers isolate entire cells, isolating cell nuclei can also lead to sample loss – this is because some nuclei, especially those found in cells of the immune system, are more structurally complex and delicate than others.
"By combining these two approaches, we were able to gain the benefits of both," says co-senior author and surgeon Dr. Ian McGilvray, who is Head of Liver and Pancreas Surgery at UHN's Sprott Department of Surgery, a surgeon and scientist at the Ajmera Transplant Centre, TGHRI Senior Scientist and Professor at U of T's Department of Surgery. "Fully characterizing the composition of the liver is crucial to understanding healthy liver function as well as disease – and this new combined approach brings us closer to achieving this."
The team also released an online app, created by Dr. Tallulah Andrews, to enable sharing and browsing of the human liver spatial transcriptomics data included in the study. Use the app and view the data
This work was supported by the Chan Zuckerberg Initiative DAF; the U of T's Medicine by Design initiative, which receives funding from the Canada First Research Excellence Fund; the U.S. National Institutes of Health; the Natural Sciences and Engineering Research Council of Canada; the Ontario Government; the Canadian Network on Hepatitis C, which is funded by a joint initiative of the Canadian Institutes of Health Research and the Public Health Agency of Canada; PSC Partners Seeking a Cure Canada; and UHN Foundation.
Dr. Slyper consults for Genentech. Dr. Regev owns stock and holds intellectual property rights with Celsius and Immunitas. Dr. Regev owns stock in Roche and Neogene.